These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12165029)

  • 1. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
    Treiber G; Ammon S; Malfertheiner P; Klotz U
    Helicobacter; 2002 Aug; 7(4):225-31. PubMed ID: 12165029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori eradication therapy.
    Suzuki H; Nishizawa T; Hibi T
    Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
    Sotoudehmanesh R; Malekzadeh R; Vahedi H; Dariani NE; Asgari AA; Massarrat S
    Digestion; 2001; 64(4):222-5. PubMed ID: 11842278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
    Fakheri H; Bari Z; Sardarian H
    Helicobacter; 2012 Aug; 17(4):264-8. PubMed ID: 22759325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
    Gisbert JP; Pajares JM
    Helicobacter; 2005 Oct; 10(5):363-72. PubMed ID: 16181345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Rescue' therapies for the management of Helicobacter pylori infection.
    Di Mario F; Cavallaro LG; Scarpignato C
    Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
    Tang D; Yuan L; Yue C; Cai T; Yao Y; Wang F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):772-778. PubMed ID: 30124214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new look at anti-Helicobacter pylori therapy.
    Chuah SK; Tsay FW; Hsu PI; Wu DC
    World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
    Isakov V; Domareva I; Koudryavtseva L; Maev I; Ganskaya Z
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1277-82. PubMed ID: 12144577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
    Nagahara A; Miwa H; Ogawa K; Kurosawa A; Ohkura R; Iida N; Sato N
    Helicobacter; 2000 Jun; 5(2):88-93. PubMed ID: 10849057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
    Nyssen OP; Pérez-Aisa Á; Tepes B; Rodrigo-Sáez L; Romero PM; Lucendo A; Castro-Fernández M; Phull P; Barrio J; Bujanda L; Ortuño J; Areia M; Brglez Jurecic N; Huguet JM; Alcaide N; Voynovan I; María Botargues Bote J; Modolell I; Pérez Lasala J; Ariño I; Jonaitis L; Dominguez-Cajal M; Buzas G; Lerang F; Perona M; Bordin D; Axon T; Gasbarrini A; Marcos Pinto R; Niv Y; Kupcinskas L; Tonkic A; Leja M; Rokkas T; Boyanova L; Shvets O; Venerito M; Bytzer P; Goldis A; Simsek I; Lamy V; Przytulski K; Kunovský L; Capelle L; Milosavljevic T; Caldas M; Garre A; Mégraud F; O'Morain C; Gisbert JP;
    Helicobacter; 2020 Jun; 25(3):e12686. PubMed ID: 32173974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
    Zhang W; Chen Q; Liang X; Liu W; Xiao S; Graham DY; Lu H
    Gut; 2015 Nov; 64(11):1715-20. PubMed ID: 26338726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.